Among 24 such systems (called devices in FDA parlance) authorized since 2015, FDA summaries for 14 lacked data on the ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Let’s keep it simple: If you want to delay Alzheimer’s onset, focus on walking and adding nutritious foods, such as walnuts, ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...

Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

New tests and new treatments are presenting more options for certain patients with Alzheimer's disease. “Today a confluence ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease ...

ALZpath’s pTau217 antibody was released in 2023 and continues to be a key focus in Alzheimer’s disease research and ...